|
1
|
Klasa-Mazurkiewicz D1, Jarząb M, Milczek
T, Lipińska B and Emerich J: Clinical significance of VEGFR-2 and
VEGFR-3 expression in ovarian cancer patients. Pol J Pathol.
62:31–40. 2011.PubMed/NCBI
|
|
2
|
Nishida N, Yano H, Komai K, Nishida T,
Kamura T and Kojiro M: Vascular endothelial growth factor C and
vascular endothelial growth factor receptor 2 are related closely
to the prognosis of patients with ovarian carcinoma. Cancer.
101:1364–1374. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kieran MW, Kalluri R and Cho YJ: The VEGF
pathway in cancer and disease: Responses, resistance, and the path
forward. Cold Spring Harb Perspect Med. 2:a0065932012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Secord AA, Darcy KM, Hutson A, Lee PS,
Havrilesky LJ, Grace LA and Berchuck A; Gynecologic Oncology Group
study. Co-expression of angiogenic markers and associations with
prognosis in advanced epithelial ovarian cancer: A Gynecologic
Oncology Group study. Gynecol Oncol. 106:221–232. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Goodheart MJ, Ritchie JM, Rose SL,
Fruehauf JP, De Young BR and Buller RE: The relationship of
molecular markers of p53 function and angiogenesis to prognosis of
stage I epithelial ovarian cancer. Clin Cancer Res. 11:3733–3742.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kamat CD, Green DE, Warnke L, Thorpe JE,
Ceriello A and Ihnat MA: Mutant p53 facilitates pro-angiogenic,
hyperproliferative phenotype in response to chronic relative
hypoxia. Cancer Lett. 249:209–219. 2007. View Article : Google Scholar
|
|
7
|
Farhang Ghahremani M, Goossens S, Nittner
D, Bisteau X, Bartunkova S, Zwolinska A, Hulpiau P, Haigh K,
Haenebalcke L, Drogat B, et al: p53 promotes VEGF expression and
angiogenesis in the absence of an intact p21-Rb pathway. Cell Death
Differ. 20:888–897. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Le Page C, Huntsman DG, Provencher DM and
Mes-Masson AM: Predictive and prognostic protein biomarkers in
epithelial ovarian cancer: Recommendation for future studies.
Cancers (Basel). 2:913–954. 2010. View Article : Google Scholar
|
|
9
|
de Graeff P, Crijns AP, de Jong S, Boezen
M, Post WJ, de Vries EG, van der Zee AG and de Bock GH: Modest
effect of p53, EGFR and HER-2/neu on prognosis in epithelial
ovarian cancer: A meta-analysis. Br J Cancer. 101:149–159. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hata K, Watanabe Y, Nakai H, Hata T and
Hoshiai H: Expression of the vascular endothelial growth factor
(VEGF) gene in epithelial ovarian cancer: an approach to anti-VEGF
therapy. Anticancer Res. 31:731–738. 2011.PubMed/NCBI
|
|
11
|
Ledermann JA, Marth C, Carey MS, Birrer M,
Bowtell DD, Kaye S, McNeish I, Oza A, Scambia G, Rustin G, et al:
Role of molecular agents and targeted therapy in clinical trials
for women with ovarian cancer. Int J Gynecol Cancer. 21:763–770.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
WMA Declaration of Helsinki - Ethical
Principles for Medical Research Involving Human Subjects.
[http://www.wma.net/en/30publications/10policies/b3/index.html.
|
|
13
|
Trimbos JBVI, Vergote I, Bolis G,
Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta
G, Scarfone G, et al; EORTC-ACTION collaborators. European
Organisation for Research and Treatment of Cancer-Adjuvant
ChemoTherapy in Ovarian Neoplasm. Impact of adjuvant chemotherapy
and surgical staging in early-stage ovarian carcinoma: European
Organisation for Research and Treatment of Cancer-Adjuvant
ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst.
95:113–125. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kononen J, Bubendorf L, Kallioniemi A,
Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G
and Kallioniemi OP: Tissue microarrays for high-throughput
molecular profiling of tumor specimens. Nat Med. 4:844–847. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Seidal T, Balaton AJ and Battifora H:
Interpretation and quantification of immunostains. Am J Surg
Pathol. 25:1204–1207. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Köbel M, Kalloger SE, Boyd N, McKinney S,
Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, et al:
Ovarian carcinoma subtypes are different diseases: Implications for
biomarker studies. PLoS Med. 5:e2322008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Skirnisdottir I and Seidal T: Association
of p21, p21 p27 and p21 p53 status to histological subtypes and
prognosis in low-stage epithelial ovarian cancer. Cancer Genomics
Proteomics. 10:27–34. 2013.PubMed/NCBI
|
|
18
|
Paley PJ, Staskus KA, Gebhard K, Mohanraj
D, Twiggs LB, Carson LF and Ramakrishnan S: Vascular endothelial
growth factor expression in early stage ovarian carcinoma. Cancer.
80:98–106. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shen GH, Ghazizadeh M, Kawanami O, Shimizu
H, Jin E, Araki T and Sugisaki Y: Prognostic significance of
vascular endothelial growth factor expression in human ovarian
carcinoma. Br J Cancer. 83:196–203. 2000.PubMed/NCBI
|
|
20
|
Engels K, du Bois A, Harter P,
Fisseler-Eckhoff A, Kommoss F, Stauber R, Kaufmann M, Nekljudova V
and Loibl S: VEGF-A and i-NOS expression are prognostic factors in
serous epithelial ovarian carcinomas after complete surgical
resection. J Clin Pathol. 62:448–454. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li J, Li L, Li Z, Gong G, Chen P, Liu H,
Wang J, Liu Y and Wu X: The role of miR-205 in the VEGF-mediated
promotion of human ovarian cancer cell invasion. Gynecol Oncol.
137:125–133. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bast RC Jr: Biomarkers for ovarian cancer:
new technologies and targets to address persistently unmet needs.
Dis Markers. 8:161–166. 2010.
|
|
23
|
Burger RA: Role of vascular endothelial
growth factor inhibitors in the treatment of gynecologic
malignancies. J Gynecol Oncol. 21:3–11. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Perren TJ, Swart AM, Pfisterer J,
Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P,
Cervantes A, Kurzeder C, et al: A phase 3 trial of bevacizumab in
ovarian cancer. N Engl J Med. 365:2484–2496. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Abu-Rustum N, Chi D, Coleman RL, del Campo
JM, Fotopoulou C, Frumovitz M, Gershenson DM, Gonzalez A, Jhingran
A, Ledermann J, et al: Summary of the 2014 MD Anderson
International Meeting in Gynecologic Oncology: Emerging therapies
in gynecologic cancer. Gynecol Oncol. 134:6–9. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang X, Qin J and Qin A: Three
polymorphisms of vascular endothelial growth factor (936C > T,
-460C > T, and -2578C > A) and their susceptibility to
ovarian cancer: A meta-analysis. Int J Gynecol Cancer. 25:779–785.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tang C, Hess K, Jardim DL, Gagliato Dde M,
Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, et
al: Synergy between VEGF/VEGFR inhibitors and chemotherapy agents
in the phase I clinic. Clin Cancer Res. 20:5956–5963. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hicklin DJ and Ellis LM: Role of the
vascular endothelial growth factor pathway in tumor growth and
angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar
|
|
29
|
Adham S, Sher I and Coomber BL: Abstract
#4284: Blockade of VEGFR2/KDR increases malignancy in human
epithelial ovarian carcinoma. Cancer Res. 69:42842009.
|
|
30
|
Adham SA, Sher I and Coomber BL: Molecular
blockade of VEGFR2 in human epithelial ovarian carcinoma cells. Lab
Invest. 90:709–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
